PanTera

TLDR

PanTera is a Mol-based joint venture producing actinium-225 for targeted cancer radiotherapy, having raised EUR 134M including EUR 93M led by EQT Life Sciences, the largest Belgian life sciences raise on record.

Overview

Founded in Mol in 2022 as a joint venture between SCK CEN (Belgian Nuclear Research Centre) and IBA (Ion Beam Applications), PanTera is developing large-scale production capacity for actinium-225, a radioactive isotope used in targeted alpha therapy for cancer treatment.

Actinium-225 is in extremely short global supply relative to demand from pharmaceutical companies developing next-generation radiopharmaceutical drugs. PanTera's facility in Mol, which already hosts one of Europe's major nuclear research sites, is positioned to become a key supplier to this growing therapeutic category.

The company raised EUR 93M led by EQT Life Sciences as part of a EUR 134M total raise, the largest single life sciences funding round in Belgian history. The capital supports production scale-up and regulatory validation of supply chains for pharmaceutical-grade actinium-225.

Funding History

• Growth round, EUR 93M (EUR 134M total), 2024: EQT Life Sciences (lead)

Key People

• Sven Van den Berghe - Founder and CEO